Kiss Flora, Buslig Julia, Szegedi Istvan, Scholtz Beata, Kappelmayer Janos, Kiss Csongor
Department of Clinical Biochemistry and Molecular Pathology, Medical and Health Sicence Center, University of Debrecen, Debrecen, Hungary.
Pediatr Blood Cancer. 2008 Feb;50(2):372-5. doi: 10.1002/pbc.21388.
In relapsed/refractory childhood acute lymphoblastic leukemia (ALL) of the B-cell lineage rituximab, a monoclonal anti-CD20 antibody was used successfully in some cases. We report on a 15-year-old female with relapsed CD20-positive B-cell progenitor ALL treated with rituximab because of positive minimal residual disease signals after chemotherapy, as checked by flow cytometry and real time quantitative-PCR. Rituximab eliminated the CD20-positive subpopulation, but not the more immature leukemic cells. The patient died with fulminant aspergillosis before hematopoietic stem cell transplantation could be performed.
在复发性/难治性B细胞系儿童急性淋巴细胞白血病（ALL）中，单克隆抗CD20抗体利妥昔单抗在某些病例中成功使用。我们报告了一名15岁女性，患有复发性CD20阳性B细胞祖细胞ALL，因化疗后经流式细胞术和实时定量PCR检查发现微小残留病信号呈阳性，接受了利妥昔单抗治疗。利妥昔单抗消除了CD20阳性亚群，但未消除更不成熟的白血病细胞。该患者在能够进行造血干细胞移植之前死于暴发性曲霉病。
